Sinovac Files 2013 Annual Report on Form 20-F

                Sinovac Files 2013 Annual Report on Form 20-F

PR Newswire

BEIJING, April 16, 2014

BEIJING, April 16, 2014 /PRNewswire/--Sinovac Biotech Ltd. (Nasdaq: SVA), a
leading provider of biopharmaceutical products in China that focuses on the
research, development, manufacturing and commercialization of vaccines,
announced today that it has filed its 2013 Annual Report on Form 20-F with the
U.S. Securities and Exchange Commission for the year ended December 31, 2013
on April 16, 2014. The Annual Report on Form 20-F is now available on the
Company's website under SEC Filing in the Investor Relations section.

The Company will provide a hard copy of its complete audited financial
statements to its shareholders upon request, free of charge. Requests for a
hard copy of the 2013 Annual Report can be made through the Contact IR page in
the Investor Relations section of the Company's website by submitting complete
mailing details on the request form.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses
on the research, development, manufacturing and commercialization of vaccines
that protect against human infectious diseases including hepatitis A and B,
seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine
flu) and mumps, as well as animal rabies vaccine for canines. The Company
recently concluded the phase III clinical trial for enterovirus 71 (against
hand, foot and mouth disease) and filed new drug application with China Food &
Drug Administration. In 2009, Sinovac was the first company worldwide to
receive approval for its H1N1 influenza vaccine, Panflu.1, and has
manufactured it for the Chinese Central Government, pursuant to the
government-stockpiling program. The Company is also the only supplier of the
H5N1 pandemic influenza vaccine to the government-stockpiling program. Sinovac
is developing a number of new pipeline vaccines including vaccines for
pneumococcal polysaccharides, pneumococcal conjugate, varicella and rubella.
Sinovac sells its vaccines mainly in China and exports selected vaccines to
Mongolia, Nepal, and the Philippines. Sinovac has also been granted a license
to commercialize seasonal flu vaccine in Mexico.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are
made under the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be
identified by words or phrases such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar statements.
Among other things, the business outlook and quotations from management in
this press release contain forward-looking statements. Statements that are not
historical facts, including statements about Sinovac's beliefs and
expectations, are forward-looking statements. Forward-looking statements
involve inherent risks and uncertainties. A number of important factors could
cause actual results to differ materially from those contained in any
forward-looking statement. Sinovac does not undertake any obligation to update
any forward-looking statement, except as required under applicable law.

Helen Yang/Chris Lee
Sinovac Biotech Ltd.
Tel: +86-10-8279-9659/9696
Fax: +86-10-6296-6910

Stephanie Carrington
The Ruth Group
Tel: +1-646-536-7017

Aaron Estrada
The Ruth Group
Tel: +1-646-536-7028

SOURCE Sinovac Biotech Ltd.

Press spacebar to pause and continue. Press esc to stop.